Research programme: fibrotic disease therapeutics - Evotec/Fibrocor
Latest Information Update: 06 Feb 2017
At a glance
- Originator Fibrocor Therapeutics
- Developer Evotec AG; Fibrocor Therapeutics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis